Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

WESTBOROUGH, Mass., Jan. 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.

"This notice of allowance from the USPTO is of high importance for RXi's Intellectual Property position in the RNAi field, and more specifically in the space of skin and organ fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Our sd-rxRNA compound, RXI-109 targeting CTGF, has already demonstrated excellent safety results in our Phase 1 trials and has confirmed the mechanism of action of this self-delivering RNAi in humans in a dose dependent manner. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds, reinforcing the potential for future commercial and business development opportunities."

About RXI-109

RXi Pharmaceuticals' first clinical program involves RXI‑109, a self-delivering RNAi compound (sd‑rxRNA®) developed for the reduction of dermal scarring. RXI‑109 is designed to reduce the expression of CTGF, a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI‑109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the Connective Tissue Growth Factor protein an
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  An entire month is dedicated to one ... Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease affecting ... atrophy, weakness, and foot and hand deformities. CMT affects ... CMT is a progressive disease, and over time patients ... devices such as leg braces, wheelchairs and scooters to ...
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2
... (Nasdaq: NKTR ) announced today that Bharatt ... Operating Officer and Head of the,PEGylation Business Unit. ... the PEGylation Business Unit, including research,and manufacturing, as ... also,serve as Chairman of Nektar India Pvt., Ltd. ...
... 22 Edwards Lifesciences,Corporation (NYSE: EW ... of heart valves,today announced the opening of ... North Crescent, Singapore. The state-of-the-art facility produces,Edwards, ... also serves as the headquarters for Edwards, ...
... Celldex,Therapeutics (a wholly-owned subsidiary of AVANT,Immunotherapeutics)(Nasdaq: ... CDX-110, being developed for the treatment of Glioblastoma,Multiforme ... presentation at the 44th,Annual Meeting of the American ... be held at McCormick Place in Chicago from ...
Cached Biology Technology:Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3Edwards Lifesciences Opens New Singapore Heart Valve Facility 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 2AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting 3
(Date:9/18/2014)... Becoming invisible is probably the ultimate form of camouflage: ... you. And this strategy is not as uncommon as ... Maryland Baltimore County, USA, explains that the larval life ... is one part of the anatomy that most creatures ... compound eyes have to shield each individual eye unit ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
(Date:9/17/2014)... professor and his doctoral student have designed a device ... collected from fog and dew., The device could provide ... around the globe., Cheng Luo, professor in the Mechanical ... in the same College of Engineering department, published "Bioinspired ... ACS, (American Chemical Society) Applied Materials & ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2
... Abroad ReportedWALL, N.J., Jan. 19 BIO-key International, ... finger-based biometric identification and wireless public safety solutions, ... the media on its fingerprint biometrics identification solutions ... 8th edition of This Week in Consumer ...
... latest American Chemical Society (ACS) Weekly PressPac from the Office ... journals and Chemical & Engineering News . Please credit ... source for this information. ARTICLE #1 FOR IMMEDIATE RELEASE ... , Analytical Chemistry In a macabre discovery ...
... SHORES, Calif., Jan. 14 Communication Intelligence Corporation ... leading supplier of electronic signature solutions for business ... recognized leader** in biometric signature verification will be ... an independent technology and market research company that ...
Cached Biology News:BIO-key(R) Fingerprint Biometrics Media Spotlights 2BIO-key(R) Fingerprint Biometrics Media Spotlights 3American Chemical Society's weekly PressPac -- Jan. 14, 2009 2American Chemical Society's weekly PressPac -- Jan. 14, 2009 3American Chemical Society's weekly PressPac -- Jan. 14, 2009 4American Chemical Society's weekly PressPac -- Jan. 14, 2009 5American Chemical Society's weekly PressPac -- Jan. 14, 2009 6CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 2CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 3CIC to Host Webinar Featuring Independent Research Firm: 'Enabling Straight Through Processing - Why the Insurance Industry Needs Electronic Signature Technology' 4
...
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
... Cells and TriEx Insect Cell Medium are ... constructs. This cell/medium combination has been selected ... high protein expression levels observed specifically with ... note that our Ready-Plaque Sf9 Cells and ...
...
Biology Products: